Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
0.1098
-0.0032 (-2.83%)
At close: Jun 2, 2026, 4:00 PM EDT
0.0975
-0.0123 (-11.20%)
Pre-market: Jun 3, 2026, 5:45 AM EDT
Aditxt Revenue
Aditxt had revenue of $12.16K in the quarter ending March 31, 2026, with 1,094.40% growth. This brings the company's revenue in the last twelve months to $14.34K, down -74.09% year-over-year. In the year 2025, Aditxt had annual revenue of $3.20K, down -97.62%.
Revenue (ttm)
$14.34K
Revenue Growth
-74.09%
P/S Ratio
0.15
Revenue / Employee
$551
Employees
26
Market Cap
2.11K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.20K | -130.79K | -97.62% |
| Dec 31, 2024 | 133.99K | -511.19K | -79.23% |
| Dec 31, 2023 | 645.18K | -288.54K | -30.90% |
| Dec 31, 2022 | 933.72K | 828.68K | 788.96% |
| Dec 31, 2021 | 105.03K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 29.57M |
| Ensysce Biosciences | 4.71M |
| Scinai Immunotherapeutics | 1.31M |
| Onconetix | 735.20K |
| Biodexa Pharmaceuticals | 104.90K |
| Aspire Biopharma Holdings | 34.56K |
ADTX News
- 1 day ago - Aditxt appoints Busch as interim CEO - TheFly
- 1 day ago - Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders - Business Wire
- 19 days ago - Aditxt announces 1-for-27 reverse stock split - TheFly
- 19 days ago - Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026 - Business Wire
- 6 weeks ago - Aditxt announces publication featuring Ignite Proteomics subsidiary - TheFly
- 6 weeks ago - Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients - Business Wire
- 7 weeks ago - Aditxt files to sell 148.28M shares of common stock for holders - TheFly
- 2 months ago - Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer - Business Wire